DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Beta Blockade in Critical Injury

Information source: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information obtained from ClinicalTrials.gov on August 08, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Trauma

Intervention: Propranolol (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Summary

Critically injured patients endure a period of hypermetabolism/catabolism after being resuscitated. The metabolic cost of this may be measured in loss of lean body mass, poor wound healing, susceptibility to infection and long hospital stays. While there have been some data to suggest that hypermetabolism can be ameliorated in burn patients by beta blockade, to our knowledge, a prospective trial in trauma patients has not yet been done. Our hypothesis is that nonselective beta blockade will reduce catabolism, improve glucose control, blunt loss of lean body mass, decrease infections and improve outcome in a cohort of critically injured patients.

Clinical Details

Official title: Beta-Blockade Reduces Catabolism in Severely Injured Trauma Patients

Study design: Treatment, Randomized, Open Label, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Primary outcome:

Lean body mass

ICU length of stay

Infectious complications

Secondary outcome:

Metabolic rate

Glucose control

Nitrogen Balance

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- ISS>25, stable at 48 hours after injury

- Fully resuscitated

- Ventilated

Exclusion Criteria Include:

- Intracranial hypertension requiring active treatment

- Hypotension/Pressors

- Already on beta blocker for a standard indication

Locations and Contacts

Denver Health Medical Center, Denver, Colorado 80204, United States; Recruiting
Debi Talamonti, Phone: 303-436-5657, Email: debi.talamonti@dhha.org
Jeff Johnson, MD, Principal Investigator
Additional Information


Last updated: July 10, 2007

Page last updated: August 08, 2008

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014